Neural Bases of Pharmacological Treatment of Nicotine Dependence - Insights from Functional Brain Imaging: A Systematic Review
- 505 Downloads
Nicotine dependence is difficult to treat, and the biological mechanisms that are involved are not entirely clear. There is an urgent need to develop better drugs and more effective treatments for clinical practice. A critical step towards accelerating progress in medication development is to understand the neurobehavioral effects of pharmacotherapies on clinical characteristics associated with nicotine dependence.
This review sought to summarize the functional magnetic resonance imaging (fMRI) literature on smoking cessation with the aim to better understand the neural processes underlying the effects of nicotinic and non-nicotinic pharmacological smoking cessation treatments on specific symptoms of nicotine dependence and withdrawal.
We conducted a search in Pubmed, Web of Science and PsycINFO databases with the keywords ‘fMRI’ or ‘functional magnetic resonance imaging’ and ‘tobacco’ or ‘nicotine’ or ‘smok*’. The date of the most recent search was May 2012.
Study Eligibility Criteria, Participants and Interventions
The original studies that were included were those of smokers or nicotine-dependent individuals, published in the English language, with pharmacological treatment for nicotine dependence and use of fMRI with blood oxygen level-dependent (BOLD) imaging or continuous arterial spin labelling (CASL). No date limit was applied.
Study Appraisal and Synthesis Methods
Two of the authors read the abstracts of all studies found in the search (n = 1,260). The inclusion and exclusion criteria were applied, and 1,224 articles were excluded. In a second step, the same authors read the remaining 36 studies. Nineteen of the 36 articles were excluded. The results were tabulated by the number of individuals and their mean age, the main sample characteristics, smoking status, study type and methodology, and the main fMRI findings.
Seventeen original fMRI studies involving pharmacological treatment of smokers were selected. The anterior and posterior cingulate cortex, medial and lateral orbitofrontal cortex, ventral striatum, amygdala, thalamus and insula are heavily involved in the maintenance of smoking and nicotine withdrawal. The effects of varenicline and bupropion in alleviating withdrawal symptoms and decreasing smoking correlated with modulation of the activities of these areas. Nicotine replacement therapy seems to improve cognitive symptoms related to withdrawal especially by modulating activities of the default-network regions; however, nicotine replacement does not necessarily alter the activities of neural circuits, such as the cingulate cortices, that are associated with nicotine addiction.
The risk of bias in individual studies, and across studies, was not assessed, and no method of handling data and combining results of studies was carried out. Most importantly, positron emission tomography (PET) studies were not included in this review.
Conclusions and Implication of Key Findings
fMRI studies delineate brain systems that contribute to cognitive deficits and reactivity to stimuli that generate the desire to smoke. Nicotinic and non-nicotinic pharmacotherapy may reduce smoking via distinct neural mechanisms of action. These findings should contribute to the development of new medications and discovery of early markers of the therapeutic response of cigarette smokers.
Conflict of interest
Drs. Menossi, Goudriaan, Périco, Nicastri, Andrade, D’Elia, Li, and Castaldelli-Maia have no conflicts of interest related to the content of this review.
Sources of funding
- 1.Royal College of Physicians. Harm reduction in nicotine addiction: helping people who can’t quit. A report by the Tobacco Advisory Group of the Royal College of Physicians. London: RCP; 2007.Google Scholar
- 13.Loughead J, Ray R, Wileyto EP, Ruparel K, O'Donnell GP, Senecal N, Siegel S, Gur RC, Lerman C. Brain activity and emotional processing in smokers treated with varenicline. Addict Biol. 2013;18(4):732–8.Google Scholar
- 16.Franklin TR, Wang Z, Sciortino N, Harper D, Li Y, Hakun J, Kildea S, Kampman K, Ehrman R, Detre JA, O’Brien CP, Childress AR. Modulation of resting brain cerebral blood flow by the GABA B agonist, baclofen: a longitudinal perfusion fMRI study. Drug Alcohol Depend. 2011;117(2–3):176–83.PubMedCrossRefGoogle Scholar
- 22.Janes AC, Frederick B, Richardt S, Burbridge C, Merlo-Pich E, Renshaw PF, Evins AE, Fava M, Kaufman MJ. Brain fMRI reactivity to smoking-related images before and during extended smoking abstinence. Exp Clin Psychopharmacol 2009;17(6):365–73. (Erratum in: Exp Clin Psychopharmacol 2010;18(3):296).Google Scholar
- 29.Staley JK, Krishnan-Sarin S, Cosgrove KP, Krantzler E, Frohlich E, Perry E, Dubin JA, Estok K, Brenner E, Baldwin RM, Tamagnan GD, Seibyl JP, Jatlow P, Picciotto MR, London ED, O’Malley S, van Dyck CH. Human tobacco smokers in early abstinence have higher levels of beta2* nicotinic acetylcholine receptors than nonsmokers. J Neurosci. 2006;26:8707–14.PubMedCrossRefGoogle Scholar
- 39.Behrens TEJ, Johansen-Berg H, Woolrich MW, Smith SM, Wheeler-Kingshott CAM, Boulby PA, Barker GJ, Sillery EL, Sheehan K, Ciccarelli O, Thompson AJ, Brady JM, Matthews PM. Non-invasive mapping of connections between human thalamus and cortex using diffusion imaging. Nat Neurosci. 2003;6:750–7.PubMedCrossRefGoogle Scholar
- 42.Strong DR, Kahler CW, Leventhal AM, Abrantes AM, Lloyd-Richardson E, Niaura R, Brown RA. Impact of bupropion and cognitive-behavioral treatment for depression on positive affect, negative affect, and urges to smoke during cessation treatment. Nicotine Tob Res. 2009;11(10):1142–53.PubMedCrossRefGoogle Scholar
- 47.Addolorato G, Leggio L, Ferrulli A, Cardone S, Bedogni G, Caputo F, Gasbarrini G, Landolfi R. Dose-response effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial. Alcohol Alcohol. 2011;46(3):312–7.PubMedCrossRefGoogle Scholar
- 54.Stead LF, Perera R, Bullen C, Mant D, Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2008;23(1):CD000146.Google Scholar
- 55.Stead LF, Perera R, Bullen C, Mant D, Hartmann-Boyce J, Cahill K, Lancaster T. Nicotine replacement therapy for smokng cessation. Cochrane Database Syst Rev 2012;11:CD000146.Google Scholar
- 69.Langleben DD, Ruparel K, Elman I, Loughead JW, Busch EL, Cornish J, Lynch KG, Nuwayser ES, Childress AR, O’Brien CP. Extended-release naltrexone modulates brain response to drug cues in abstinent heroin-dependent patients. Addict Biol 2012 [Epub ahead of print].Google Scholar
- 72.Moeller SJ, Honorio J, Tomasi D, Parvaz MA, Woicik PA, Volkow ND, Goldstein RZ. Methylphenidate enhances executive function and optimizes prefrontal function in both health and cocaine addiction. Cereb Cortex 2012 [Epub ahead of print].Google Scholar
- 73.Bush G, Holmes J, Shin LM, Surman C, Makris N, Mick E, Seidman LJ, Biederman J. Atomoxetine increases fronto-parietal functional MRI activation in attention-deficit/hyperactivity disorder: a pilot study. Psychiatry Res. 2013;211(1):88–91.Google Scholar